Antibiofilm agent-22 

Antibiofilm agent-22 is an FpvA receptor-targeting antibacterial agent. Antibiofilm agent-22 chelates iron, disrupts las, pqs, and rhl pathways, reduces elastase, pyocyanin, and rhamnolipid production, and induces bacterial iron starvation. Antibiofilm agent-22 can be used for the research of Pseudomonas aeruginosa infection^[1].

Antibiofilm agent-22 (Compound 5j) potently inhibits Pseudomonas aeruginosa PAO1 biofilm formation without direct bactericidal activity, with an IC₅₀ of 2.66 μM^[1].
Antibiofilm agent-22 (1.25-20 μM; overnight) inhibits biofilm development in Pseudomonas aeruginosa PAO1 in a concentration-dependent manner^[1].
Antibiofilm agent-22 (1.25-20 μM) significantly and concentration-dependently reduces production of elastase, pyocyanin, and rhamnolipids in Pseudomonas aeruginosa PAO1, with maximum inhibition at 20 μM^[1].
Antibiofilm agent-22 (1.25-20 μM; 24 h) inhibits the las, pqs, and rhl quorum sensing systems in Pseudomonas aeruginosa PAO1 without affecting GFP protein expression or bacterial growth^[1].
Antibiofilm agent-22 (1.25-20 μM) acts as a potent iron chelator (pFe(III) = 22.99) that concentration-dependently enhances pyochelin and pyoverdine production in Pseudomonas aeruginosa PAO1 by inducing iron starvation^[1].
Antibiofilm agent-22 (24 h) disrupts iron homeostasis and impairs processes critical to biofilm formation (including pilus assembly) in Pseudomonas aeruginosa PAO1 via transcriptomic dysregulation^[1].
Antibiofilm agent-22 and its Fe³⁺ dimer exhibit strong, stable binding affinity to the Pseudomonas aeruginosa FpvA receptor, competing with native pyoverdine to disrupt iron acquisition^[1].
Antibiofilm agent-22 (1.25-20 μM) inhibits swarming motility in Pseudomonas aeruginosa PAO1 in a concentration-dependent manner (78% inhibition at 20 μM) and induces cytoplasmic vacuolization and membrane thinning without direct bactericidal activity^[1].
Antibiofilm agent-22 acts synergistically with Tobramycin (HY-B0441) against Pseudomonas aeruginosa PAO1, reducing the antibiotic's MIC by 32-fold (FICI = 0.078)^[1].
Antibiofilm agent-22 (3.125-50 μM) exhibits no significant hemolytic activity against rabbit erythrocytes at concentrations up to 50 μM^[1].
Antibiofilm agent-22 (6.25-100 μM; 24 h) shows no significant cytotoxicity to RAW 264.7, HSC, or 293T cells at concentrations up to 100 μM after 24-hour incubation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antibiofilm agent-22 (Compound 5j) (25 μM; topical; daily for 3 or 9 days) plus Tobramycin sulfate (HY-B0441A) achieve near-complete bacterial clearance from the wounds in mice P. aeruginosa single-species infection model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

410.55

C₂₂H₃₈N₂O₅

O=C1C=C(COCCCCCCC(NO)=O)N(CCCCCCCCC)C=C1O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jia X, et al. A dual-targeting strategy: Novel 6-substituted 3-Hydroxypyridin-4(1H)-one-hydroxamate conjugates against Pseudomonas aeruginosa biofilm. Bioorg Chem. 2026 Jul 5;175:109837.